Muscular Dystrophy Association Renews Partnership with ALS Therapy Development Institute to Develop New Treatments for Lou Gehrig's Disease
CAMBRIDGE, Mass. and TUCSON, Ariz., Jan. 6 Buoyed by the extraordinary progress being made by the ALS Therapy Development Institute, the Muscular Dystrophy Association today announced a new milestone-driven grant of $2.5 million, adding to the $18 million MDA already has invested with ALS TDI -- the world's only non-profit research center focused exclusively on developing treatments for amyotrophic lateral sclerosis (ALS). The funding comes through MDA's fast-track ALS research fundraising initiative, Augie's Quest, which already has granted $21.7 million for promising ALS work since June 2006.
"MDA has seen an enormous return on its investment in ALS TDI during the past three years. Thanks in part to this strategic research partnership, scientists are accelerating knowledge about amyotrophic lateral sclerosis while zeroing in on a variety of promising therapeutic approaches. We're excited about the rapid progress ALS TDI has made on bringing several promising drug candidates to the most crucial stages of preclinical development," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors.
Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease) is a progressive, fatal neurodegenerative disease affecting approximately 30,000 people in the United States at any given time. The average survival following diagnosis is only about 36 months, and onset can occur in teenage years plus every decade of adulthood. ALS usually progresses rapidly, with patients losing their ability to move, speak, swallow, and eventually breathe on their own. Currently, there is neither a cure nor an effective treatment for ALS.
"The support and guidance that the MDA has provided ALS TDI researchers has led to some very exciting outcomes. With this additional investment, we hope to turn the tide on this disease and deliver a variety of well validated therapeutic options for clinical trial," said Steven Perrin, Ph.D., chief executive officer and chief scientific officer of ALS TDI.
When it received its first MDA Augie's Quest installment in late 2006, ALS TDI quickly identified and filled critical technology and talent gaps at its state-of-the-art research center, located in the Cambridge biotech hub of Kendall Square. ALS TDI now boasts an industrial scale drug development pipeline that integrates unbiased discovery technologies with rigorous drug development capabilities. The progress of the first phase of the collaboration exceeded all expectations, delivering the first validated therapeutic that ALS TDI has ever tested. This drug, known as ALS TDI 00846, is a blocking antibody to CD40L which ALS TDI is now in the process of partnering for clinical development.
The two organizations began this historic collaboration three years ago when fitness pioneer Augie Nieto, diagnosed with ALS in 2005, partnered with MDA to raise funds for ALS research and therapeutic development. The result, MDA's Augie's Quest, was created as a fast-track ALS research funding initiative aimed at filling the drug development gap for ALS. Over the past four years, Augie's Quest has raised $21.7 million for MDA-funded translational research seeking effective treatments for ALS. Notable scientific projects previously funded by Augie's Quest include: work at the University of California at Irvine ($500,000); at Targeted Genetics Corporation in Phoenix ($652,000); and by ALS TDI ($18 million investment 2007-2009).
"My entire life I spent teaching people the importance of physical fitness. But I didn't just preach it. I lived it and led by example. When I was told I had this disease, I knew I needed to do the same thing and make a difference. We have surpassed the original fundraising goal through Augie's Quest. But we aren't stopping there, and we will not stop until ALS is stopped," said Augie Nieto, chairman of ALS TDI, chief inspirational officer of Augie's Quest and national co-chairman, with his wife Lynne, of the MDA'S ALS Division.
The renewed contract announced today includes an initial milestone payment of $2.5 million with mechanisms to add additional milestones and associated funding at the discretion of the MDA steering committee. Progress towards meeting milestones will be assessed quarterly by a review board comprised by representatives from both organizations and non-affiliated, outside researchers recognized for their expertise in ALS research.
About Augie's Quest
Fitness pioneer Augie Nieto started Augie's Quest (www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness of Chicago, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005, and Augie's Quest raises money primarily through a variety of special events, including "Fight Night" in Tustin, CA; Augie's Quest Bash in San Diego, CA; "Tradition of Hope" in Los Angeles, CA; "Celebrity Golf Classic" in Phoenix, AZ; "Gift of Time: St. Patty's Day Bash" in Denver, CO; "Field of Hope Gala" in New Jersey; "Secure A Cure Golf Classic" in Purchase, NY; "Big Canyon Golf" in Newport Beach, CA; The ClubCorp Charity Classic at golf clubs nationwide; plus "Clubs for A Cure" special visitation benefits for Augie's Quest at La Fitness and Bally Total Fitness locations across the country, as well as at scores of other independent and regional health clubs.
MDA (www.mda.org) is the world's largest nonprofit provider of ALS services and funder of ALS research. Over the years, MDA has invested $230 million specifically fighting ALS. MDA operates more than 200 clinics at hospitals across the county, 36 of which are ALS-specific research and care centers. The Association's unparalleled health care services, research, advocacy and education programs provide help and hope to more than 1 million Americans affected by ALS and 42 other neuromuscular diseases.
About ALS TDI
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, while running the world's largest efforts to pre-clinically validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs. The world's first non-profit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only non-profit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry. For more information, please visit us online at www.als.net.
Media Contacts: Jim Brown, MDA Vice President-Public Relations Robert Goldstein, ALS TDI email@example.com, 520-529-5320 firstname.lastname@example.org, 617-441-7295
SOURCE ALS Therapy Development Institute
You May Also Like